American Association for Cancer Research

sorry, we can't preview this file

23266066cir170383-sup-186621_2_supp_4434182_p0jpp5.docx (23.99 kB)

Figure S3 from Soluble SLAMF6 Receptor Induces Strong CD8+ T-cell Effector Function and Improves Anti-Melanoma Activity In Vivo

Download (23.99 kB)
journal contribution
posted on 2023-04-03, 23:21 authored by Galit Eisenberg, Roni Engelstein, Anat Geiger-Maor, Emma Hajaj, Sharon Merims, Shoshana Frankenburg, Ronny Uzana, Abraham Rutenberg, Arthur Machlenkin, Gabi Frei, Tamar Peretz, Michal Lotem

Anti-SLAMF6 antibody had no direct effect on T cell activation


Dr. Miriam and Sheldon G. Adelson Medical Research Foundation

Canadian Institutes of Health Research

International Development Research Centre

Israel Science Foundation

Deutsche Forschungsgemeinschaft



SLAMF6, a member of the SLAM (signaling lymphocyte activation molecules) family, is a homotypic-binding immune receptor expressed on NK, T, and B lymphocytes. Phosphorylation variance between T-cell subclones prompted us to explore its role in anti melanoma immunity. Using a 203-amino acid sequence of the human SLAMF6 (seSLAMF6) ectodomain, we found that seSLAMF6 reduced activation-induced cell death and had an antiapoptotic effect on tumor-infiltrating lymphocytes. CD8+ T cells costimulated with seSLAMF6 secreted more IFNγ and displayed augmented cytolytic activity. The systemic administration of seSLAMF6 to mice sustained adoptively transferred transgenic CD8+ T cells in comparable numbers to high doses of IL2. In a therapeutic model, lymphocytes activated by seSLAMF6 delayed tumor growth, and when further supported in vivo with seSLAMF6, induced complete tumor clearance. The ectodomain expedites the loss of phosphorylation on SLAMF6 that occurs in response to T-cell receptor triggering. Our findings suggest that seSLAMF6 is a costimulator that could be used in melanoma immunotherapy. Cancer Immunol Res; 6(2); 127–38. ©2018 AACR.

Usage metrics

    Cancer Immunology Research



    Ref. manager